The platelet-derived growth factor a-receptor (PDGFR-a) displays a lineage-specific expression pattern in the mouse embryo and is required for normal development of mesoderm and cephalic neural crest derivatives. The purpose of the present study was to demonstrate the in vivo promoter function of genomic DNA fragments representing the 5′-flanking part of the human PDGFRA gene. 2.2, 0.9 and 0.4 kb PDGFRA promoter fragments, ligated to a lacZ reporter gene, were microinjected into fertilized mouse eggs and transgenic mouse lines were established. The expression patterns were basically similar in the 2.2 and 0.9 kb lines and overlapped grossly the endogenous Pdgfra gene expression pattern. The transgenic line with the highest expression level was chosen for detailed analysis. Expression was, as expected, mainly confined to tissues of mesodermal and neural crest origin. No expression was found in epithelial tissues of endo-or ectodermal origin. The promoter fragments were also active in neuroepithelium and in certain neuronal cell types that did not faithfully express PDGFR-a mRNA, while they failed to specify reporter expression in PDGFR-a expressing O-2A progenitor cells and other glial elements of the central nervous system. Thus, the isolated human PDGFRA promoter contains most but not all of the regulatory elements that are necessary to establish tissue specific gene expression during development.
Introduction
Platelet-derived growth factor (PDGF) and its receptors are expressed in a wide variety of cells during embryonic development and in the adult. As a result of the widelydistributed expression and a pleiotropy of effects (see Ross et al., 1990; Raines et al., 1991) PDGF has been postulated to play an important role in many different biological processes, including embryogenesis, wound-healing, atherosclerosis and neoplasia (Ross et al., 1986; BowenPope et al., 1991; Raines and Ross, 1993) . Two different receptors for PDGF, denoted a (PDGFR-a) and b (PDGFRb), have been characterized. They are encoded by separate genes and belong to the superfamily of protein tyrosine kinase receptors. Like their ligands, the PDGF receptors are highly homologous molecules and they form homoand heterodimers upon ligand binding (Claesson-Welsh, 1994) .
Although it is difficult to discriminate between the contribution of either receptor subunit in the different biological responses to PDGF, several studies have indicated a specific role for PDGF-A/PDGFR-a in embryonic development. Most of this information is derived from studies in mouse and Xenopus embryos. In the mouse pre-implantation embryo, PDGF-A and the PDGFR-a are co-expressed in all cells from the two-cell stage onwards (Rappolee et al., 1988; Palmieri et al., 1992) . Following implantation, however, the expression patterns of PDGF-A and PDGFR-a become separated. PDGF-A becomes localized mainly to the ectoderm, whereas PDGFR-a expression becomes restricted to the mesoderm Palmieri et al., 1992) . A similar observation has been made in Xenopus embryos, where mesoderm induction establishes this lineage-specific pattern of ligand and receptor gene expression (Jones et al., 1993) . PDGF-B and the PDGFRb have not been detected in pre-implantation embryos. However, the b-receptor subunit is expressed shortly after implantation with a comparable, but more restricted distribution than the PDGFR-a (Mercola et al., 1990) .
The functionality of the PDGFR-a in the formation of these tissues is clearly demonstrated in Patch mice, which carry a naturally-occurring deletion which includes the Pdgfra gene. Mice homozygous for this mutation display severe developmental defects in mesoderm-and neural crest-derived structures, eventually resulting in the death of the embryo Schatteman et al., 1992) . Recently, Soriano (1997) has generated Pdgfra null mice by targeted mutagenesis. Data from these mice confirm the functional importance of the PDGFR-a in development, in particular in the development of neural crest cells. Mice homozygous for a targeted disruption of the PDGF-A gene indirectly stress the importance of the PDGFR-a in embryonic development. Most of the PDGF-A mutant mice die before day 10 post coitum (p.c.), and the remaining mice die early post-natally as a result of an emphysema-like phenotype in the lung (Boström et al., 1996) . In addition, extensive data has indicated that in the central nervous system (CNS) PDGF-A/ PDGFR-a is essential for the development of certain glial precursor cells, the oligodendrocyte-type 2 astrocyte (O-2A) progenitor cells Raff et al., 1988; Richardson et al., 1988; Barres et al., 1992) .
The mechanisms that control the time and tissue specific expression of the PDGFR-a are currently unknown. Several growth-modulating factors, which are also expressed in the developing embryo, transmodulate PDGFR-a expression in vitro. This includes transforming growth factor-b (Gronwald et al., 1989; Battegay et al., 1990; Yamakage et al., 1992; Paulsson et al., 1993; Yeh et al., 1993a; Bonner et al., 1995) , fibroblast growth factor (McKinnon et al., 1990; Tsukamoto et al., 1991; Schöllmann et al., 1992; Bonner et al., 1996) and retinoic acid (Mercola et al., 1990; Wang et al., 1990; Mosselman et al., 1994; Tsukamoto et al., 1994) .
We have recently cloned and characterized the 5-flanking region of the human PDGFRA gene and shown that retinoic acid strongly induces the promoter activity in human embryonal carcinoma cells (Afink et al., 1995) . A similar observation has been made for the mouse Pdgfra promoter (Wang and Stiles, 1994) . The rat promoter has also been characterized (Kitami et al., 1995) , and comparison of the nucleotide sequences of the three promoters shows a high degree of sequence conservation. Although these studies have established a role for the PDGFRA promoter in some regulatory aspects of PDGFR-a expression in vitro, the in vivo functionality of these promoters still remains to be shown.
In this study we assess the functionality of the isolated human PDGFRA promoter in vivo, using a transgenic mouse model. A 2.2 kb human PDGFRA promoter fragment cloned in front of a lacZ reporter gene correctly drives the bgalactosidase expression in mesoderm-and neural crestderived tissues of the developing mouse as compared with the distribution of PDGFR-a mRNA expressed from the endogenous mouse gene. Similar results can be obtained with a shorter, 0.9 kb, promoter fragment. The results indicate that 2.2 kb, and probably also 0.9 kb, upstream regulatory sequences of the human PDGFRA gene contain most, but not all, of the cis-acting elements necessary to establish tissue specific expression of the PDGFR-a.
Results

Generation and analysis of transgenic mouse lines
A total of eight transgenic founders carrying the 2.2 kb, as well as four with the 0.9 kb, and three with the 0.4 kb PDGFRA promoter fragment-lacZ transgene were established (listed in Table 1 ). The expression of lacZ was investigated in whole embryos at days 9 to 15 p.c. and in brains at days 5 to 10 postnatal (Table 1) . 2/8 2.2-lines, 3/4 0.9-lines Transgenic lines generated with the 2.2, 0.9 and 0.4 kb PDGFRA promoter-lacZ constructs. Fifteen independent transgenic founder lines were established and lacZ reporter gene expression in whole embryos at days 9-15 p.c. and/or in the brain of 5-10 days postnatal mice was determined. The different transgenic lines are identified by the promoter construct used (either 2.2, 0.9 or 0.4) and a number. The level of lacZ reporter gene expression is given as: +, distinct expression; (+), low level and sometimes diffuse expression; −, no expression; nd, not determined. and 2/3 0.4-lines showed b-galactosidase activity above background levels, but the levels of expression varied considerably among the lines. Samples from the positive lines were sectioned and the tissue distribution of lacZ expression in these lines is described in Table 2 . The 2.2-07 and 0.9-04 lines showed the strongest overall expression with a similar distribution of reporter gene activity in mesoderm-derived skeletal structures and in facial and thoracic neural crest-derived structures of the developing embryo, but only the 2.2-07 line demonstrated early expression in branchial arches and in sclerotome. In addition, the 2.2-14 line expressed lacZ in sclerotome at early time points and in bone primordia. Three lines expressed lacZ in the CNS, the 2.2-07 and 0.9-04 in postnatal cerebellum and the 2.2-07 line also in specific structures of the cerebrum. The 0.9-14 line, however, expressed lacZ only in hippocampus and cerebellar nuclei. Two 0.4 kb PDGFRA promoter-lacZ transgenic lines as well as the 0.9-10 line showed weak, diffuse expression of lacZ in whole embryos or localized and sometimes inconsistent expression. However, the localization of expression to cranial ganglia and bladder was noted both in the 0.4-01 and 0.4-03 lines and this overlapped with part of the expression pattern of the 2.2-07 and 0.9-04 lines. Fig. 1 . Comparison of PDGFRA-promoter-lacZ transgene expression with endogenous PDGFR-a mRNA expression in whole mounts of embryos of the transgenic mouse line 2.2-07. Days 10.5-12.5 p.c. embryos were subjected to whole-mount b-galactosidase staining (B,D,F) or exposed to whole-mount in situ hybridization using a mouse PDGFR-a cRNA probe (A,C,E). A and B illustrate the overlapping expression pattern of PDGFR-a mRNA and lacZ in cranio-facial mesenchyme, branchial arches (arrowheads) and ventral portion of somites, while a dorsal view (C,D) demonstrates the overlapping expression in the perineurotome (arrowheads) and forelimb buds (fl). D and F in addition demonstrate the ectopic expression of the lacZ reporter gene along the neural tube in the spinal cord area, in the rhombencephalon with the rhombic lip and in the thalamic region (arrowheads). The specific pattern of expression in each transgenic line was maintained from generation to generation, but, as described in Table 2 , the details of distribution varied among lines. This is well conceivable since the activity of the short promoter fragments used in this work might easily be influenced by the activities of surrounding mouse geno- S-mRNA in situ hybridization were photographed in dark field (A,D,M) and bright field (B,E). D and E represent a double bgalactosidase staining/PDGFR-a mRNA in situ hybridization. In transverse sections strong PDGFR-a mRNA expression is seen in sclerotome, but not in dorsal root ganglia (g) and notochord (arrowhead) (A,B). The lacZ expression (C) has a partly similar distribution to the PDGFR-a mRNA, but cannot be demonstrated in the medial part of the sclerotome where PDGFR-a mRNA signals are strongest. A parasagittal section (D,E) through the dorsal sclerotome, perineurotome and dorsal root ganglia (g) of a b-galactosidase-stained embryo was subjected to PDGFR-a mRNA in situ hybridization. This procedure illustrates the overlapping expression pattern in the dorsal portion of the developing vertebral primordium (arrowheads). Whole-mount PDGFR-a mRNA in situ hybridization (F) and sectioning through the developing forelimb following whole-mount b-galactosidase staining (G) also demonstrate a similar expression pattern of the endogenous gene and the reporter gene in the carpal/metacarpal region. The skeleton of a day 8 postnatal transgenic mouse was subjected to whole-mount b-galactosidase staining and activity was found in the cartilaginous tissue of ribs and vertebral bodies (arrowhead) (H) and in the epiphyseal plates of long bones (arrowheads) (I). A transverse section through the upper thoracic region and thymus of a day 14.5 p.c. embryo (J) also illustrates the widespread lacZ expression in perichondrium/periosteum and in chondroid structures. LacZ is for example expressed in the perichondrium/ periosteum of the sternum (arrowheads), developing neural arches (na) and forelimb bones. In general, lacZ expression was seen both in the perichondrium (arrowhead) and in chondrocytes, here exemplified by the cartilaginous tip of a forming phalangeal bone (K) and the femural primordium (L), while PDGFRa mRNA signals were concentrated in the perichondrium, as demonstrated by in situ hybridization of a sagittal section through the humerus head (M). mic sequences. The majority of b-galactosidase-expressing lines, however, expressed the reporter gene in mesodermand neural crest-derived mesenchymal structures as well as in certain cells of the nervous system, while no activity was found in epithelial tissues of ecto-or endodermal origin. The only exception was the 0.9-14 line, where lacZ was expressed mainly in epithelial cells of the liver. This finding was interpreted as an ectopic pattern of expression in that specific line, probably resulting from the site of integration of the transgene.
Expression of lacZ in the 2.2-07 transgenic mouse line: comparison with the distribution of endogenous PDGFR-a mRNA
The strongest overall lacZ expression and the most complete distribution of expression was found in the 2.2-07 line. This line was therefore chosen for a more detailed analysis of the cell and tissue distribution of reportergene activity in comparison with endogenous PDGFR-a mRNA levels. The results obtained by whole-mount bgalactosidase staining and whole-mount PDGFR-a 35 SmRNA in situ hybridization are presented in Fig. 1 . Most b-galactosidase-positive areas were found to co-localize with areas of PDGFR-a mRNA signals. A major exception was, however, the neural tube and brain, which displayed bgalactosidase activity but not PDGFR-a mRNA, in wholemounts. A more detailed comparison based on embryo sections also visualized mainly overlapping expression patterns, but divergent patterns in the CNS. This is described below, illustrated in Figs. 2-4 and summarized in Table 3 .
Sclerotome
No b-galactosidase-positive cells were found at day 7.5 p.c., neither in embryonic nor in extra-embryonic parts. At day 8.5 p.c. lacZ expression appeared in somites and in the first branchial arch and it subsequently followed the somite formation pattern, starting in the cervical region and spreading cranio-caudally (Fig. 1B,D,F) . Around day 12.5 p.c., the somite-derived segmentally-arranged sclerotome, dermatome and myotome appear and at this stage lacZ expression was mainly seen in the sclerotome and, less intensively, in the mesenchyme of the developing dermis, but not in the myotome (Fig. 2C ). This distribution of lacZ reporter gene activity follows that of the endogenous Pdgfra gene expression Schatteman et al., 1992 ; this work). However, the lacZ reporter gene was not expressed in the whole sclerotome, as is the PDGFR-a mRNA, but was confined to the Fig. 3 . Comparison of lacZ and PDGFR-a mRNA expression in other mesenchymal structures. Days 13 (B,C,D), 14.5 (A,E,F,G,I) and 15 (H) p.c. embryos from the 2.2-07 transgenic line were investigated by whole-mount b-galactosidase staining followed by sectioning (A,E,F,G,H,I) or investigated by PDGFRa 35 S-mRNA in situ hybridization using embryo sections (B,C,D). The in situ hybridizations were photographed in dark field (B,D) and in bright field (C). A sagittal section through the facial region shows prominent lacZ expression in a well-demarcated area of the lip mesenchyme (arrowhead) (A), while PDGFRa mRNA signals diffusely cover the whole facial mesenchyme (B,C). Arrowheads point out an area of the developing lower lip corresponding to the one shown in A. In contrast to the b-galactosidase activity, there is no particular concentration of mRNA in this region. A sagittal section through the upper thoracic region shows PDGFR-a mRNA expressed in the mesenchyme (arrowhead) of the developing thymus (th) (D). As illustrated in a transverse section lacZ expression was likewise found in the interstitial mesenchyme of the thymus (th) (E). The lacZ expression in the tracheal wall mesenchyme (arrowhead) is demonstrated in the same section. LacZ expression was also concentrated in the mesenchyme of the developing nostrils (arrowhead) (F) and in the condensed mesenchyme (arrowhead) apposing the involuted epithelium of the developing vibrissae hair follicles (G,H). LacZ was strongly expressed in the lung interstitial mesenchyme and in localized areas of the heart, here exemplified by an area of the septum (arrowhead) (I).
condensed lateral and dorsal sclerotome portion (Fig.  2C,D,E) . The area of the sclerotome that surrounds the notochord lacked b-galactosidase staining but expressed PDGFR-a mRNA at a high level, while the notochord itself was negative for both PDGFR-a and b-galactosidase ( Fig.  2A-C) .
Neural crest-derived structures, skin and internal organs
In mouse development, the mesenchyme of the first and second branchial arches are of neural crest origin and later differentiate into facial and neck muscles and cartilages. PDGFR-a mRNA has previously been demonstrated in neural crest-derived tissues Ho et al., 1994) . Consistent with this, lacZ was expressed in the mesenchyme of the first branchial arch at day 8.5 p.c. and in the maxillary and mandibular processes at day 12.5 p.c. (Fig. 1) . As investigated at day 12.5 p.c., PDGFR-a mRNA was strongly and diffusely expressed in all areas of the cranial neural crest mesenchyme, while the lacZ reporter activity at this stage was confined to more restricted areas (Fig. 3A-C) . Thus, strong lacZ expression was found in well demarcated areas of mesenchyme in the upper and lower lips (Fig. 3A) , eyelids, nostrils (Fig. 3F ) and pharynx. These b-galactosidase-positive areas showed a subepithelial distribution and were detected during the stage of modeling of these structures.
The basal part of the heart is also known to be of cranial neural crest origin. As expected Schatteman et al., 1995) , both b-galactosidase and PDGFRa mRNA signals were found in the heart (Fig. 3I ) and were concentrated in endocardial cushions, forming heart-valves and the walls of the large arteries at the base of the heart (not shown).
The condensed mesenchyme of the future vibrissae and dermal hair papillae displayed b-galactosidase staining (Fig.  3 G,H) . These specialized structures of dermal derivation are known to express PDGFR-a mRNA Takakura et al., 1996) .
PDGFR-a mRNA is also expressed in the interstitial mesenchyme of most developing internal organs and the lacZ reporter gene showed a similar pattern of activity (Table 3 , Fig. 3D ,E), in that lacZ was expressed in mesenchymal but not in epithelial cells. The mesenchyme of the tracheal wall and the interstitial mesenchyme of the lung, pancreatic primordium and urogenital sinus expressed lacZ during the organogenesis stage at days 9.5 to 15.5 p.c. At day 15.5 p.c., an abundance of b-galactosidase-positive cells were present in the interstitial lung tissue (Fig. 3I) , while the level of expression started to decline one week postnatally and had disappeared at around 20 days postnatally (data not shown). Urinary bladder mesenchyme showed strong lacZ expression from the embryonic stage until adulthood. LacZ expression was, however, not detected in the diaphragm, or in the esophagus, stomach and intestinal walls.
Bone primordia, periosteum/perichondrium and cartilage
Most bones form as mesenchyme condensations that subsequently chondrify and ossify. Whole-mount b-galactosidase staining revealed lacZ expression in developing limb buds and in the chondrifying bone primordia of limbs, vertebrae and ribs. Expression was especially strong at the stage of precartilaginous condensation and in the periosteum/perichondrium during the formation of these structures, as investigated from day 12.5 to 15.5 p.c. (Fig. 2J) . In addition, staining could be seen in the primordia of the Tissue distribution of lacZ reporter gene expression in the 2.2-0.7 PDGFRA promoter-lacZ transgenic line compared with the distribution of endogenous mouse PDGFR-a mRNA. For most tissues the comparisons were made at days 12.5-13 p.c., for specific areas of facial mesenchyme and for dermal hair papillae at day 14.5 p.c. and for cerebrum, cerebellum and brain-stem at days 0-5 postnatal. Levels of lacZ reporter gene expression were estimated on a four-grade scale (−, +, ++, +++), using sections from embryos and tissues that had been b-galactosidase stained as wholemounts. In situ hybridizations were performed on sections from paraformaldehyde fixed embryos and tissues. The PDGFR-a 35 S-mRNA in situ hybridization signals were determined by counting the number of silver grains overlying 30 cells for every tissue and the result is given as the mean number of grains/cell: −, ≤ 2; +, 5-10; ++, 10-15; +++, Ͼ15. membrane bones of the skull (data not shown). This lacZ expression pattern corresponded with the distribution of endogenous PDGFR-a mRNA (Fig. 2F ,G,K,L,M) . However, chondrified bone primordia and cartilage were negative for PDGFR-a mRNA, while the lacZ expression was maintained in chondrocytes ( Fig. 2J-Fig. 4 . Comparison of lacZ and PDGFR-a mRNA expression in the central nervous system. Cerebral tissue from day 8 postnatal mice (A,B,C,D) and cerebellar tissue from day 5 postnatal (E, F) and adult (G,H) mice were investigated. Coronal sections of both cerebral cortex (A,B,C,D) and cerebellum (E,F,G,H) from brains stained for b-galactosidase activity (B,C,D,G) are shown. Some sections were subjected to 35 S-mRNA in situ hybridization with a PDGFR-a cRNA probe (A,B,E,F) and/or immunostained with MAP2 (C) and GFAP (D,H) antibodies. MAP2 is a dendritic 'marker' present in most neurons in the gray matter and GFAP is an astrocyte specific 'marker'. Dark field (A) and bright field (B) photographs of a section from the cerebral cortex, subjected to both b-galactosidase staining and in situ hybridization, show that lacZ (blue cells) and PDGFR-a mRNA are expressed in different cells. Double bgalactosidase staining and MAP2 immunostaining demonstrates that the b-galactosidase-positive cells (blue) express MAP2 protein (brown) (arrowheads) (C), while double b-galactosidase staining and GFAP immunostaining of a section adjacent to that presented in A and B shows that the b-galactosidasepositive cells do not express GFAP (D). Dark field (E) and bright field (F) photographs of a cerebellar section subjected to in situ hybridization show distinct PDGFR-a mRNA signals over scattered cells in the molecular layer (arrowheads). As demonstrated in a cerebellar cryosection lacZ-expressing cells (blue color) have a similar scattered distribution in the molecular (ml) and granular (gl) layers to the PDGFR-a mRNA-expressing cells. LacZ expression can however not be demonstrated in the white matter (wm) (G), where abundant PDGFR-a mRNA expressing cells are normally present (not shown). GFAP immunoreactive glial cells (brown) are concentrated in the cerebellar white matter (H). The Purkinje cells as well as the granular neurons themselves were bgalactosidase-and PDGFR-a mRNA-negative. A b-galactosidase-stained day 8 postnatal brain (upper right corner) was coronally cut in the mid-forebrain region illustrating that lacZ is expressed in layered structures of the cerebral parietal cortex (I). The distribution of lacZ gene expression in the cerebellum of mice from the 2.2-07 (left) and 0.9-04 (middle) transgenic lines is similar as illustrated by samples from adult mice (J). The brain to the right is from a nontransgenic littermate. (K) shows lacZ expression in neurons of the trigeminal ganglion of a day 2 postnatal mouse and (L) shows expression in a subset of the ventral motor neurons (arrowheads) and more diffusely in the dorsal part of the spinal cord. This section is from the area of the upper thoracic region of a day 14.5 p.c. embryo. L). Thus, at day 8 postnatal lacZ expression was found in the cartilaginous epiphyseal plates of the long bones and in developing metacarpal/metatarsal bones, but was absent from the diaphyseal regions that had already ossified (Fig.  2H,I ). Likewise, lacZ expression was absent from the ossified centers of the vertebrae but present in their cartilaginous laminae. All cartilaginous structures investigated showed lacZ expression postnatally, and the cartilaginous ribs, for example, stained heavily (Fig. 2H,J) . Tracheal cartilage expressed lacZ for a longer period than lung mesenchymal tissue. The blue staining appeared in whole-mounts of this tissue for more than 200 days postnatally.
Central nervous system
In the mouse embryo, the neural tube closes at days 9 to 10 p.c. LacZ expression was not detected in the neural tube and brain at this time point, but appeared at day 12.5 p.c. as a spotted staining in certain areas, such as in the neuroepithelium at the dorsal aspect of the central canal, in the roof of the third ventricle, in the epithalamus, hypothalamus and rhombencephalon (Fig. 1F) . Strong expression was seen in the rhombic lip which is the origin of the future cerebellum. However, all these sites were negative for PDGFR-a mRNA (Fig. 1E) , while the choroid plexus, which is known to express a high level of PDGFR-a mRNA, lacked b-galactosidase staining (data not shown). The thin roof of the fourth ventricle, which develops the choroid plexus, did not stain with X-gal at this point in time, neither did the choroid plexus at other embryonic and postnatal stages.
At day 5 postnatal sheet and/or dot shaped areas of bgalactosidase-positive cells were present in several sites of the brain, including the cerebral parietal cortex, olfactory bulb, hypothalamus, thalamus, pontine nuclei and hippocampus (Fig. 4I) . Distinctly PDGFR-a positive cells were at this time found in the cerebral cortex as well as scattered throughout the depth of the brain tissue (Fig. 4A) . However, these cells were not expressing lacZ. As shown in Fig. 4B , and judged on their distribution and morphology, the PDGFR-a positive cells most likely represent the O-2A progenitor cells (Pringle et al., 1992) . On the contrary, the shape and the size of the b-galactosidase-positive cells of the cerebral cortex, as well as their distribution in lamellated structures (Fig. 4B,I ), strongly suggested that they were neuronal cells. Whereas lacZ expression was highest before and around birth and declined shortly thereafter, the majority of PDGFR-a expressing O-2A progenitor cells develop postnatally. This nature of the PDGFR-a mRNA and bgalactosidase-positive cell populations, respectively, was confirmed by glial fibrillary acidic protein (GFAP) (Fig.  4D ) and microtubule associated protein-2 (MAP2) (Fig.  4C) immunohistochemical stainings.
Principally similar findings were made in other areas of the CNS. At days 5-8 postnatal, the strongest reporter gene expression was found in the cerebellum (Fig. 4I,J) , where abundant b-galactosidase-positive cells covered the molecular and granular layers. However, b-galactosidase staining was absent from the cerebellar white matter and meninges (Fig. 4G) , as well as from the brain-stem, where many PDGFR-a positive glial precursor cells were present (not shown). Scattered cells in the molecular and granular layers of the cerebellum also expressed PDGFR-a mRNA and these cells were distributed similarly to the b-galactosidase-positive cells in these layers (Fig. 4E-G) .
LacZ expression was not found in the eye or in the optic nerve at day 12.5 p.c., day 15.5 p.c. or postnatally (not shown), although previous in situ hybridization studies showed PDGFR-a mRNA to be expressed in cells of the retina and eye lens as well as in the O-2A progenitor cells of the optic nerve and spinal cord Mudhar et al., 1993; Reneker and Overbeek, 1996) . LacZ expression could not be demonstrated in O-2A progenitor cells of the developing spinal cord either (Fig. 4L) . O-2A progenitor cells are there known to appear as a small group of cells at the ventro-lateral aspect of the central canal. Instead, lacZ-positive cells were closely packed in groups arrayed along the longitudinal axis of the spinal cord at a distance from the central canal, dorsally as well as in ventrolateral positions, most probably corresponding to subsets of neuronal cells. In addition, cephalic ganglion cells, which are of neural crest origin, expressed lacZ (Fig. 4K) .
Thus, the lacZ and PDGFR-a mRNA expression patterns were clearly divergent in the developing CNS (Figs. 1, and  4) , as found in the cerebrum, cerebellum and spinal cord. The 2.2 kb PDGFRA promoter fragment did not specify PDGFRA gene expression in O-2A progenitor cells or other glial elements, but displayed activity in several neuronal cell types.
Discussion
The expression of the PDGFR-a is strictly regulated during embryonic development (for a review, see: Ataliotis and Mercola, 1997) . To investigate the molecular mechanisms involved in the regulation of PDGFR-a expression we cloned the human PDGFRA promoter region and established its functionality in vitro (Afink et al., 1995) . In the present paper we have investigated the in vivo functionality of this promoter region in a transgenic mouse model.
The data clearly show that an isolated 2.2 kb human PDGFRA promoter fragment can establish the correct spatio-temporal gene expression in most mesoderm-and neural crest-derived tissues. From this, it can be concluded that most of the regulatory elements are contained within this relatively short stretch of 5′-flanking sequences. Although not studied in detail, results in transgenic mice with a 0.9 kb promoter construct indicate that even 825 bp upstream of exon 1 may already contain many of these regulatory elements. A 0.4 kb promoter fragment established only a minor part of this pattern. Although none of the lines completely mimicked the endogenous Pdgfra expression pattern, the general lineage specificity was followed, in that reporter gene expression occurred in mesenchymal and nervous tissues, but not in ecto-and endodermally-derived epithelial tissues.
The current data also demonstrate that transcriptional regulation is the main mechanism by which PDGFR-a mRNA expression is controlled during embryonic development. Although some of the discrepancies between lacZ and Pdgfra expression patterns in these transgenic mice (see below) may be the result of additional (post-transcriptional) regulatory mechanisms, the major part of the regulation takes place at the promoter level.
There were several areas in the transgenic mice where PDGFR-a mRNA and b-galactosidase were not co-localized, in particular in the CNS. PDGFR-a mRNA expression patterns in the CNS have been extensively described (especially in rat), and expression seems to be mainly confined to the O-2A progenitor cells (Pringle et al., 1992; Yeh et al., 1993b ). Although we found intense b-galactosidase staining in the CNS of several transgenic lines, this staining was not localized to the presumptive O-2A progenitor cells. Instead, our data indicate that these b-galactosidase-positive cells are neurons, which do not express detectable levels of PDGFR-a mRNA. The reason for this discrepancy between Pdgfra and LacZ expression patterns is currently not known. We do not think that the integration site of the transgene is responsible for the observed expression patterns in the CNS, since the same pattern was found in two independent transgenic lines with two different promoter constructs. Moreover, in the same transgenic lines the promoter fragments directed a correct spatio-temporal expression pattern in most mesoderm-and neural crest-derived tissues.
Alternative promoter usage may be a mechanism used by the organism to regulate PDGFR-a mRNA expression. Besides the promoter region used in this study, two alternative promoters within the PDGFRA gene have been identified. Kraft et al. (1996) describe a promoter within intron 12 of PDGFRA which gives rise to two alternative PDGFR-a transcripts of 1.5 and 5 kb in human embryonal carcinoma cells. However, the resulting shorter transcript length makes it unlikely that this promoter drives PDGFR-a mRNA expression in O-2A progenitor cells, since it has been shown that these cells contain the regular 6.4 kb transcript (McKinnon et al., 1990) . A better candidate would be the alternative promoter, which has been characterized in growth-arrested mouse fibroblasts (Lih et al., 1996) . This promoter has been localized within intron 1 of the Pdgfra gene, and its usage would also result in a 6.4 kb PDGFR-a mRNA. However, sequence analysis of 5′ ends of PDGFR-a mRNA isolated from O-2A progenitor cells has indicated that this alternative promoter is not used by these cells (W.D. Richardson, pers. commun.) . More likely is that the isolated promoter fragment does not contain all the regulatory elements which are required for the complete proper expression of the Pdgfra.
The transgene was also expressed in undifferentiated neuroepithelium of the 2.2-07 and 0.9-04 lines. Recent reports indicate that uncommitted neural stem cells do indeed express PDGFR-a (Johe et al., 1996) and that only a short transient activation of the PDGFR-b or -a kinase can have a major impact on the fate of neuroepithelial cells (Williams et al., 1997) . In the CNS of the 2.2-07 transgenic line, lacZ was heavily expressed in neuroepithelial cells of the developing rhombencephalon and the rhombic lip. These areas constitute the precursors of cephalic neural crest and cerebellar cells. Both these cell populations contain multipotent, highly migratory stem cells that can give rise to multiple differentiated cell types. Mouse neuroepithelial cells of the cerebellar external granular layer that form from the rhombic lip have the capacity to differentiate into both neuronal and glial cell types (Gao and Hatten, 1994) . Also in other experimental systems the existence of a common neuron and oligodendrocyte precursor cell has been indicated (Williams et al., 1991; Richardson et al., 1997) . It is therefore possible that the lacZ positive neuroepithelial cells at some time point display a low and transient, here undetectable, level of PDGFR-a mRNA. In certain mature neuronal subpopulations the lacZ reporter gene expression may even reflect the endogenous gene activity, as indicated here in the molecular and granular layers of the cerebellum (Fig.  4E-G) . We interpret the described scattered PDGFR-a positive and lacZ positive cells as representing a subset of cerebellar interneurons, a possibility that remains to be proven. Other mature neuronal cell types which expressed the lacZ reporter gene, such as cells in the cerebral cortex, olfactory bulb, hippocampus and spinal cord ventral motor neurons (Vignais et al., 1995 : Oumesmar et al., 1997 and ganglion cells (Eccleston et al., 1993) have indeed been described in the literature to express the PDGFR-a. It can, thus, be postulated that regulatory components which specify the receptor downregulation in most developing neuronal cell types and upregulation or persistence in O-2A progenitor cells, are missing in the transgene, but the exact cause of these discrepancies is currently not known. Additional experiments are being undertaken to investigate the details of the PDGFRA promoter activity in the CNS.
Another discrepancy between lacZ and Pdgfra expression patterns was the lack of reporter gene activity in medial sclerotome regions surrounding the notochord. It is well known that the ventral and dorsal parts of the somites (Brand-Saberi et al., 1996) and different areas of the sclerotome (Mo et al., 1997) are characterized by the expression of different subsets of transcription factors. One common denominator of ventral sclerotome cells and oligodendrocyte precursors is their inducibility by sonic hedgehog (Roelink et al., 1994; Chiang et al., 1996; Poncet et al., 1996; Pringle et al., 1996) , a major ventralizing agent synthesized in the notochord (Echelard et al., 1993) . It may therefore be postulated that the isolated PDGFRA fragment does not contain the proper cis-acting element(s) involved in the associated PDGFR-a induction. A shorter, 0.9 kb, promoter fragment did not drive reporter gene expression in sclerotome cells at all (Table 2a and data not shown).
Other discrepancies were the failure to downregulate reporter gene expression during chondrocyte differentiation and the finding of localized areas of b-galactosidase staining that did not correspond to increased PDGFR-a mRNA levels in the facial mesenchyme. Here, as well as in the CNS and sclerotome cells discussed above, alternatives to transcriptional regulation may also play a role in controlling PDGFR-a mRNA levels. However, the current experimental approach does not allow investigation of other regulatory mechanisms. Thus, the contribution of post-transcriptional mechanisms to the cell type specific expression of PDGFRa mRNA remains obscure. The relatively long half-life of the b-galactosidase reporter, making it impossible to monitor a sudden decrease of transcriptional activity, has to be considered. In addition, differences between species may account for some of the discrepancies in expression pattern. Although the PDGFRA upstream regulatory sequences are very well conserved between man, mouse and rat (Afink et al., 1995; Kitami et al., 1995; Wang and Stiles, 1994) , there may be differences in regulatory mechanisms or expression patterns which we are not aware of at present.
The PDGFRA promoter lacZ reporter transgenic approach is an illustrative way of demonstrating gene expression in vivo, and the data highlight the involvement of the PDGFR-a in skeletal, neural crest, skin, lung and CNS development. The relevance of these observations is supported by the developmental defects found in Patch mutant mice, described as subepidermal blisters, cleft face, heart abnormalities, a kinked neural tube and skeletal defects (Grüneberg and Truslove, 1960) . The presence of PDGFRA promoter activity in the interstitial mesenchyme of internal organs, as well as the concentration of reporter gene activity to dermal hair papillae, nostrils and eyelids, strengthens the notion that PDGF paracrine stimulatory mechanisms play an important role in the proper modeling of these tissues, resulting in epithelial-mesenchymal interactions and cell movements. PDGF is known to be expressed in epithelia of both ecto-and endodermal origin Boström et al., 1996; Souza et al., 1996) , which therefore provide sources for the ligand. Likewise, the presence of PDGFRA promoter activity in fusing midline structures (Table 2a , Fig. 2J ) is consistent with the finding that lack of PDGFR-a function plays a causative role in spina bifida (Helwig et al., 1995; Payne et al., 1997) . Most of these developmental events involve the movement and remodeling of mesoderm-derived tissues. At even earlier stages of development, PDGF has been implicated in the spreading of mesoderm cells (Symes and Mercola, 1996) .
Since expression of the PDGFRA gene is indispensable for the formation of many mesoderm-and neural crestderived structures OrrUrtreger et al., 1992; Schatteman et al., 1992) , further elucidation of the gene expression control mechanisms will provide relevant information about the molecular mechanisms involved in the formation of these embryonic structures.
Experimental procedures
Generation of transgenic mice
Approximately 2.2-, 0.9-and 0.4-kb genomic DNA fragments encompassing nucleotides −2120 to +129, −825 to +129 and −441 to +129, respectively, of the human PDGFRA gene (Afink et al., 1995) were cloned into the HindIII site of the lacZ reporter vector pCH110 (Pharmacia) using standard molecular biological techniques (Sambrook et al., 1989) . Before injection, the PDGFRA promoter-lacZ fragments were excised from the vector with AvrII and BamHI (Promega), recovered from agarose gel and purified by electroelution. The resulting DNA fragments, at a concentration of 1-2 mg/ml, were microinjected into pronuclei of fertilized B6CBAF1 (Bommice) mouse eggs. Transgenic founder mice were identified by PCR analysis of 20 days postnatal pup tail DNA, using lacZ (5′-TAAGCCGTAGA-TAAACAGGC-3′) and PDGFRA promoter (5′-CACC-CAGTCTTGTACACACA-3′) specific primers. Positive results were confirmed by Southern blot analysis with a 32 P-labeled lacZ DNA probe. Screening for lacZ expression was performed by whole-mount b-galactosidase staining of postnatal brains and/or of embryos. No obvious differences were observed between the growth and behavior of transgenic and normal mice.
b-Galactosidase staining of whole-mount embryos and tissues
Embryos were dissected out free of extracellular membranes. Starting at day 13.5 p.c. X-gal penetration of whole embryos was insufficient. To allow better penetration of the substrate, embryos after this stage were opened by incision prior to staining. At postnatal stages tissues, such as brain, lung, bladder, ribs, sternum and long bones, were dissected out.
Embryos and tissues were fixed in 2% paraformaldehyde in phosphate-buffered saline (PBS) for 1-2 h depending on the size. After three rinses in PBS, embryos and tissues were permeabilized in PBS containing 2 mM MgCl 2 , 0.02% NP40, 0.01% Na-deoxycholate three times for 20 min at room temperature. Staining was performed by incubation in 1 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-galactoside (X-gal, Promega), in PBS containing 2 mM MgCl 2 , 0.02% NP40, 0.01% Na-deoxycholate, 5 mM K 4 Fe(N) 6 , 5 mM K 3 Fe(N) 6 at 37°C overnight. The embryos and tissues were subsequently washed three times in PBS, and were either dehydrated gradually in methanol and cleared in a solution of benzyl alcohol/benzyl benzoate (1:2) for photography, or embedded in paraffin for histological studies.
Due to impaired penetration of X-gal in certain adult tissues, b-galactosidase stainings were also performed on frozen sections (Fig. 4G) . The mice were first perfused with 2% paraformaldehyde, tissues were dissected and after additional fixation in 2% paraformaldehyde for 2 h the tissues were frozen on dry ice and sectioned. The bgalactosidase staining was performed in humidified air at 37°C overnight and sections were subsequently rinsed in PBS and counterstained with hematoxylin.
Histology and immunohistochemistry
For collection of dissected tissues, the whole animal was first perfused with 2% paraformaldehyde. Embryos and tissues were paraffin-embedded according to standard protocols. 5 to 10 mm sections were cut and mounted on gelatincoated or Superfrost Plus (Fisher) slides. Part of the sections were counterstained with hematoxylin and eosin.
The immunohistochemistry was performed as described by Li et al. (1995) . Monoclonal anti-MAP2 antibody (Amersham), monoclonal anti-GFAP antibody (Labsystems, Oy) and the secondary antibody, biotinylated anti-mouse IgG (Vector laboratories) were used at a final dilution of 1:1000, 1:200 and 1:200 respectively. The immunoreactions were visualized by diaminobenzidine.
For double b-galactosidase-and immunostaining, tissues were first b-galactosidase stained as whole-mounts, then paraffin-embedded and sectioned and finally immunostained.
In situ hybridization of tissue sections and wholemount embryos
In situ hybridization on sections was performed as previously described by Svensson et al. (1995) . The PDGFR-a sense and antisense probes were in vitro transcribed from a 1.6 kb EcoRI fragment corresponding to the mouse PDGFR-a cDNA, encoding most of the extracellular domain (Mercola et al., 1990) .
For double b-galactosidase staining and PDGFR-a mRNA in situ hybridization, the in situ hybridization was performed with the 35 S-labeled cRNA probe on sections of embryos and tissues that had been b-galactosidase-stained as whole-mounts.
PDGFR-a mRNA expression in days 8.5-12.5 p.c. whole-mount embryos was detected using the method described by Günther et al. (1994) . Briefly; the PDGFR-a cRNA probe was labeled with DIG-11-UTP (Boehringer Dig RNA labeling kit) and hybridization was performed in a 50% formamide buffer at 65°C. The DIG signal was made visible by anti-DIG-alkaline phosphatase Fab fragments (Boehringer), followed by incubation with BM Purple substrate (Boehringer).
